CJC-1295 DAC | Long-Acting GHRH Research Compound Analysis

CJC-1295 DAC: The Science of Extended GHRH Signaling

The Biochemistry of CJC-1295 DAC

The molecular structure of CJC-1295 DAC is based on a modified version of the first 29 amino acids of GHRH, often referred to as Mod GRF (1-29). The critical distinction is the addition of the Drug Affinity Complex (DAC), which prevents rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). This allows the compound to remain active in research models for several days, providing a constant stimulus to the pituitary gland.

Mechanism of Action: Pituitary Stimulation and Albumin Conjugation

In advanced endocrinology and metabolic research, CJC-1295 DAC functions through several coordinated physiological pathways:

• Albumin Binding (DAC Technology): The DAC affinity allows the peptide to bind to serum albumin, extending its biological half-life from minutes to approximately 6–8 days.

• GHRH Receptor Agonism: The peptide binds to GHRH receptors in the anterior pituitary, triggering the synthesis and secretion of endogenous growth hormone.

• Sustained GH Pulsatility: Research focuses on how CJC-1295 DAC maintains the natural pulsatile nature of GH release while increasing the overall amplitude of those pulses over an extended duration.

• IGF-1 Upregulation: By providing a continuous somatotropic stimulus, the compound is studied for its ability to significantly elevate systemic levels of Insulin-like Growth Factor 1 (IGF-1).

Primary Research Applications

• Extended Secretagogue Modeling: Analyzing the impact of long-term GHRH stimulation on pituitary health and receptor sensitivity.

• Metabolic Homeostasis Research: Investigating the role of sustained GH levels in lipid metabolism and adipose tissue reduction.

• Musculoskeletal Repair: Studying the indirect effects of elevated IGF-1 on protein synthesis and the repair of soft tissues.

• Age-Related Endocrine Decline: Observing the reversal of somatopause markers in aging laboratory models through steady-state GHRH signaling.

4. Technical Specifications (E-E-A-T Data)

5. Product FAQ 

Q: How does CJC-1295 DAC differ from CJC-1295 No DAC (Mod GRF 1-29)?

A: The “No DAC” version has a very short half-life (approx. 30 minutes) and requires more frequent administration in research models. CJC-1295 DAC is designed for long-term study, remaining active in the system for over a week.

Q: Why is DAC technology significant in peptide research?

A: DAC technology allows researchers to bypass the limitation of rapid peptide clearance. It enables the study of steady-state hormone levels without the fluctuations associated with short-acting secretagogues.